Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2021-11-19
DOI
10.1080/13543784.2022.2008354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted Treatment of Triple-Negative Breast Cancer
- (2021) Joanna A. Young et al. CANCER JOURNAL
- Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
- (2021) Alessandro Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
- (2021) Alessandro Rizzo et al. Future Oncology
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
- (2021) Leisha A Emens et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
- (2021) Alessandro Rizzo et al. Cancers
- Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
- (2021) Sung Gwe Ahn et al. BREAST CANCER RESEARCH AND TREATMENT
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
- (2021) Arielle L. Heeke et al. CANCER AND METASTASIS REVIEWS
- Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
- (2021) Caroline Boman et al. CANCER TREATMENT REVIEWS
- The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
- (2021) Vincenzo Quagliariello et al. Cardiovascular Diabetology
- Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
- (2021) Alessandro Rizzo et al. Immunotherapy
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Atezolizumab for the treatment of breast cancer
- (2020) Sangeetha M. Reddy et al. Expert Review of Anticancer Therapy
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
- (2020) Diana M Merino et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
- (2020) Jin Sun Lee et al. Cancers
- PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab in triple negative breast cancer (TNBC)
- (2020) Fahad Shabbir Ahmed et al. CLINICAL CANCER RESEARCH
- Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
- (2020) Debora de Melo Gagliato et al. BIODRUGS
- Pembrolizumab and atezolizumab in triple-negative breast cancer
- (2020) Dorota Kwapisz CANCER IMMUNOLOGY IMMUNOTHERAPY
- Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors
- (2020) J. Tanner McMahon et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
- (2020) Vincenzo Quagliariello et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer
- (2020) Richard S.P. Huang et al. ONCOLOGIST
- Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
- (2020) Vincenzo Quagliariello et al. Journal of Personalized Medicine
- Triple-negative breast cancer: promising prognostic biomarkers currently in development
- (2020) Jasmine Sukumar et al. Expert Review of Anticancer Therapy
- PD-L1 testing based on SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
- (2020) Vicente Peg et al. Future Oncology
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Recent advances of immunotherapy for biliary tract cancer
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
- (2020) Abirami Sivapiragasam et al. Cancer Medicine
- PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
- (2019) Elisabeth Specht Stovgaard et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors
- (2019) Magali Svrcek et al. BULLETIN DU CANCER
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- Application of PD-1 Blockade in Cancer Immunotherapy
- (2019) Xiaomo Wu et al. Computational and Structural Biotechnology Journal
- Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
- (2019) Wenfa Huang et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Targeted Therapies for Triple-Negative Breast Cancer
- (2019) Tomas G. Lyons CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities
- (2019) Ioannis A. Voutsadakis Targeted Oncology
- Triple negative breast cancer: A thorough review of biomarkers
- (2019) Jesse Lopes da Silva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Metastatic and triple-negative breast cancer: challenges and treatment options
- (2018) Sumayah Al-Mahmood et al. Drug Delivery and Translational Research
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Genetic Markers in Triple-Negative Breast Cancer
- (2018) Zuzana Sporikova et al. Clinical Breast Cancer
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab for the treatment of triple-negative breast cancer
- (2018) Anne-Sophie Heimes et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The clinical promise of immunotherapy in triple-negative breast cancer
- (2018) Praveen Vikas et al. Cancer Management and Research
- Directing the use of DDR kinase inhibitors in cancer treatment
- (2017) Inger Brandsma et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
- (2017) Maria Vittoria Dieci et al. SEMINARS IN CANCER BIOLOGY
- Microsatellite Instability
- (2017) Liisa Chang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A Breakthrough: Macrophage-Directed Cancer Immunotherapy
- (2016) C. D. Mills et al. CANCER RESEARCH
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
- (2016) Nayoung Lee et al. PATHOLOGY
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started